Antigen-presenting cell
Targeting of Human Antigen-Presenting Cell Subsets
5
The Exonuclease Domain of Lassa Virus Nucleoprotein Is Involved in Antigen-Presenting-Cell-Mediated NK Cell Responses
10
Antigen presenting cell–derived complement modulates graft versus host disease
6
Anatomical and Cellular Requirements for the Activation and Migration of Virus-Specific CD8+ T Cells to the Brain during Theiler's Virus Infection
8
<p>Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma</p>
17
TARGETING TOOLS FOR A DNA VACCINE CARRIER, A DESIGN IN PREVENTION OF CANCER
10
Activation of CD8+ T-Cell with abacavir and HLA-B*57:01 binding peptides and elimination of T-Cell responses through chemical modification
228
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
12
Carbon nanotubes as cancer therapeutic carriers and mediators
23
MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis
22
Delivery strategies to enhance oral vaccination against enteric infections
18
T lymphocyte reactivity and antibody response to a synthetic peptide (glutamic acid alanine tyrosine) as a marker for disease resistance in chickens
133
Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient derived tumours
14
Clinical grade generation of peptide stimulated CMV/EBV specific T cells from G CSF mobilized stem cell grafts
15
The development and role of microbial-host interactions in gut mucosal immune development
10
The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
16
Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross sectional study
18
The Synthesis and Biological Evaluation of Mycobacterial p Hydroxybenzoic Acid Derivatives (p HBADs)
10
Molecular analysis of T cell receptors: Mapping T cell recognition and repertoire in two human immune responses
251
The role of ADAMTS 1, 4 and 5 in multiple sclerosis
236